CEB-01 by Cebiotex for Soft Tissue Sarcoma: Likelihood of Approval

In June, Abeona pushed back the time­line for its ap­pli­ca­tion to the FDA for ap­proval of a rare ge­net­ic skin cell ther­a­py. At the time,

The FDA approved pozelimab (Veopoz) as the first treatment for adults and children ages 1 year and up with CD55-deficient protein-losing enteropathy. Also known as

Inaqovi is a fixed-dose combination of 35mg decitabine, a hypomethylating agent, and 100mg cedazuridine, a cytidine deaminase inhibitor. Image Credit: Nemes Laszlo / Shutterstock. The